Literature DB >> 10371352

Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome.

L Lespagnard1, D Gancberg, G Rouas, G Leclercq, N de Saint-Aubain Somerhausen, A Di Leo, M Piccart, A Verhest, D Larsimont.   

Abstract

Dendritic cells (DC) are the most potent antigen-presenting cells, and induce antigen-specific immune responses. Infiltration of tumors by DC is thought to reflect the interaction between the host immune system and tumor cells. Tumor-infiltrating DC (TIDC) are believed to evolve into tumor-antigen pulsed cells and then to migrate to local lymph nodes, where they activate anti-tumor immune responses. Indirect clinical evidence supporting this theory is provided by studies showing that high TIDC densities are associated with favorable prognosis in some tumor types. In the present study, we evaluated 143 primary breast adenocarcinomas for the presence of DC, using immunohistochemistry with the anti-S100 protein antibody. We analyzed the relationship between the degree of infiltration by S100+ TIDC and the usual prognostic factors and clinical outcome. The results show that 42% of breast adenocarcinomas contain S100 TIDC. The number of S100+ TIDC varies according to the grade of tumors as follows: GRIII > GRII > GRI. A relationship is also found between S100+ TIDC and tumor size, lymph-node involvement, estrogen/progesterone receptor status and age. However, the presence of S100+ TIDC, even at the highest density, was not correlated with metastasis-free survival or overall survival.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10371352     DOI: 10.1002/(sici)1097-0215(19990621)84:3<309::aid-ijc19>3.0.co;2-3

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  26 in total

Review 1.  Chemokines and dendritic cell traffic.

Authors:  S Sozzani; P Allavena; A Vecchi; A Mantovani
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

Review 2.  Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored.

Authors:  Jan Buter; Herbert M Pinedo
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

3.  Fluorescent-tilmanocept for tumor margin analysis in the mouse model.

Authors:  Ava Hosseini; Jennifer L Baker; Christopher A Tokin; Zhengtao Qin; David J Hall; Dwayne G Stupak; Tomoko Hayashi; Anne M Wallace; David R Vera
Journal:  J Surg Res       Date:  2014-05-10       Impact factor: 2.192

Review 4.  Understanding the tumour micro-environment communication network from an NOS2/COX2 perspective.

Authors:  Debashree Basudhar; Gaurav Bharadwaj; Veena Somasundaram; Robert Y S Cheng; Lisa A Ridnour; Mayumi Fujita; Stephen J Lockett; Stephen K Anderson; Daniel W McVicar; David A Wink
Journal:  Br J Pharmacol       Date:  2018-11-06       Impact factor: 8.739

5.  Dendritic cell infiltration and prognosis of human hepatocellular carcinoma.

Authors:  Xiao-Yan Cai; Qiang Gao; Shuang-Jian Qiu; Sheng-Long Ye; Zhi-Quan Wu; Jia Fan; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-19       Impact factor: 4.553

Review 6.  Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.

Authors:  Hua Mao; Drake G Lebrun; Jingxuan Yang; Vivian F Zhu; Min Li
Journal:  Cancer Invest       Date:  2012-01       Impact factor: 2.176

7.  Angiogenesis and dendritic cell density are not correlated with metachronous distant metastasis in curatively operated rectal cancer.

Authors:  K Günther; T Radkow; M A Reymond; R Pflüger; A Dimmler; W Hohenberger; T Papadopoulos
Journal:  Int J Colorectal Dis       Date:  2003-02-08       Impact factor: 2.571

8.  HER2-specific T lymphocytes kill both trastuzumab-resistant and trastuzumab-sensitive breast cell lines in vitro.

Authors:  Xiao-Lin Lin; Xiao-Li Wang; Bo Ma; Jun Jia; Ying Yan; Li-Jun Di; Yan-Hua Yuan; Feng-Ling Wan; Yuan-Li Lu; Xu Liang; Tao Shen; Jun Ren
Journal:  Chin J Cancer Res       Date:  2012-06       Impact factor: 5.087

9.  Clinical evaluation of systemic and local immune responses in cancer: time for integration.

Authors:  Dmitriy W Gutkin; Michael R Shurin
Journal:  Cancer Immunol Immunother       Date:  2013-10-08       Impact factor: 6.968

10.  Heparanase expression, degradation of basement membrane and low degree of infiltration by immunocytes correlate with invasion and progression of human gastric cancer.

Authors:  Zun-Jiang Xie; Ying Liu; Li-Min Jia; Ye-Chun He
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.